Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered cells take on tough blood cancer in first human trial

NCT ID NCT05679895

Recruiting now Disease control Sponsor: OneChain Immunotherapeutics Source: ClinicalTrials.gov ↗

First seen Mar 13, 2026 · Last updated Jun 13, 2026 · Updated 9 times

Summary

This early-phase study tests a new treatment called OC-1, which uses a patient's own immune cells (T cells) that have been modified in a lab to recognize and attack a specific marker (CD1a) on cancer cells. The trial aims to see if this therapy is safe and can help shrink or eliminate cancer in up to 20 children and adults with T-cell acute lymphoblastic leukemia or lymphoma that has come back or not responded to standard treatments. Participants will receive a single infusion of these engineered cells and be closely monitored for side effects and cancer response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hospital Clínic

    RECRUITING

    Barcelona, Spain

    Contact

  • Hospital Sant Joan de Déu

    RECRUITING

    Barcelona, Spain

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.

LYMPHOBLASTIC T-CELL LYMPHOMA T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA